Giant cell arteritis Infliximab Full paper Randomized, 44 GCA, new 54 Did not achieve primary Hoffman TNF- blocker multi-centre, (cranial) weeks and main secondary 2007 130 double-blinded endpoints Etanercept Full Randomized, 17 GCA in 15 Cumulative GC dose: 1.5g TNF- blocker multi-centre, remission, months in ETN vs. 3.0g in control double-blinded stable oral 2008 133 (p=0.03) prednisone outcomes negative Adalimumab Full Randomized, 70 GCA, new 52 Did not achieve primary Seror 2014 TNF- blocker (cranial) weeks and main secondary 132 double-blinded endpoints Tocilizumab IL-6 receptor Full paper Randomized, 30 GCA, new or 52 Complete remission at Villiger blockade single-centre, relapsing weeks 12/52 weeks: 85%/85% in 2016 15 double-blinded TCZ vs. 40%/20% in control group (p=0.03/p=0.001) Time to relapse: 50 weeks in TCZ vs. 25 weeks in control group (p<0.001) Discontinuation of GCs: 80% in TCZ vs. 20% in control group (p=0.004) Cumulative GC dose: 43mg/kg in TCZ vs. 110mg/kg in control group (p<0.001) 52 Sustained remission at 12 weeks + Randomized, months: 56% (weekly IL-6 receptor GCA, New or 52 Stone 2016 Tocilizumab Abstract multi-centre, 251 injections), 53% (bi-weekly blockade refractory weeks 16 double-blinded injections) in TCZ vs. 14% open in control (p < 0.0001) label
Giant cell arteritis Infliximab TNF- blocker Full paper Randomized, multi-centre, double-blinded 44 GCA, new (cranial) 54 weeks Did not achieve primary and main secondary endpoints Hoffman 2007 130 Etanercept TNF- blocker Full Randomized, multi-centre, double-blinded 17 GCA in remission, stable oral prednisone 15 months Cumulative GC dose: 1.5g in ETN vs. 3.0g in control (p=0.03) outcomes negative 2008 133 Adalimumab TNF- blocker Full Randomized, double-blinded 70 GCA, new (cranial) 52 weeks Did not achieve primary and main secondary endpoints Seror 2014 132 Tocilizumab IL-6 receptor blockade Full paper Randomized, single-centre, double-blinded 30 GCA, new or relapsing 52 weeks Complete remission at 12/52 weeks: 85%/85% in TCZ vs. 40%/20% in control group (p=0.03/p=0.001) Time to relapse: 50 weeks in TCZ vs. 25 weeks in control group (p<0.001) Discontinuation of GCs: 80% in TCZ vs. 20% in control group (p=0.004) Cumulative GC dose: 43mg/kg in TCZ vs. 110mg/kg in control group (p<0.001) Villiger 2016 15 Tocilizumab IL-6 receptor blockade Abstract Randomized, multi-centre, double-blinded 251 GCA, New or refractory 52 weeks + 52 weeks open label Sustained remission at 12 months: 56% (weekly injections), 53% (bi-weekly injections) in TCZ vs. 14% in control (p < 0.0001) Stone 2016 16
170706%20Dasgupta_accepted.docx